姜黄产品对膝关节骨关节炎的影响:一项系统综述和网络荟萃分析。

IF 3.4 2区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE
Han Su Wai, Thanika Pathomwichaiwat, Thanarat Suansanae, Surakit Nathisuwan, Wipharak Rattanavipanon
{"title":"姜黄产品对膝关节骨关节炎的影响:一项系统综述和网络荟萃分析。","authors":"Han Su Wai, Thanika Pathomwichaiwat, Thanarat Suansanae, Surakit Nathisuwan, Wipharak Rattanavipanon","doi":"10.1186/s12906-025-05045-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Turmeric has traditionally been used to treat various inflammatory conditions, including knee osteoarthritis (OA). There are multiple turmeric preparations available. However, the comparative effectiveness of these products remains unknown. This study aimed to assess the comparative effectiveness of turmeric products for knee OA outcomes by conducting a systematic review and network meta-analysis of randomized, controlled trials (RCTs).</p><p><strong>Methods: </strong>PubMed, EMBASE, SCOPUS, and ClinicalTrials.gov databases were searched up to August 2024, identifying RCTs that compared turmeric preparations and/or active comparators versus placebo. The primary outcome measured pain reduction, using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), while secondary outcomes evaluated pain using other tools. Mean differences (MDs) were pooled using a random-effects model, and the concept of minimum clinically important difference (MCID) was considered.</p><p><strong>Results: </strong>Seventeen studies were included. All turmeric preparations significantly reduced WOMAC pain. The mean differences (MD, 95% CI) for WOMAC pain reduction were as follows: - 4.01 (-6.22, - 1.80) for conventional curcuminoid preparations (CT) plus active drug comparators (AC, defined as NSAIDs and acetaminophen), - 3.33 (-5.26, - 1.39) for AC, - 3.17 (-5.50, - 0.83) for CT, and - 2.47 (-3.27, - 1.67) for bioavailability-enhanced curcuminoid preparations (BE). The BE preparation also demonstrated a 30% reduction in WOMAC pain compared to placebo, reaching the MCID threshold. The BE + AC combination led to a 70% reduction in VAS pain compared to AC alone.</p><p><strong>Conclusions: </strong>All turmeric preparations appear to be effective in reducing knee OA pain when used as monotherapy compared to placebo. However, the certainty of evidence remains low, indicating a need for further research.</p><p><strong>Prospero registration number: </strong>CRD42023464749.</p><p><strong>Clinical trial number: </strong>not applicable.</p>","PeriodicalId":9128,"journal":{"name":"BMC Complementary Medicine and Therapies","volume":"25 1","pages":"292"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309109/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of turmeric products on knee osteoarthritis: a systematic review and network meta-analysis.\",\"authors\":\"Han Su Wai, Thanika Pathomwichaiwat, Thanarat Suansanae, Surakit Nathisuwan, Wipharak Rattanavipanon\",\"doi\":\"10.1186/s12906-025-05045-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Turmeric has traditionally been used to treat various inflammatory conditions, including knee osteoarthritis (OA). There are multiple turmeric preparations available. However, the comparative effectiveness of these products remains unknown. This study aimed to assess the comparative effectiveness of turmeric products for knee OA outcomes by conducting a systematic review and network meta-analysis of randomized, controlled trials (RCTs).</p><p><strong>Methods: </strong>PubMed, EMBASE, SCOPUS, and ClinicalTrials.gov databases were searched up to August 2024, identifying RCTs that compared turmeric preparations and/or active comparators versus placebo. The primary outcome measured pain reduction, using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), while secondary outcomes evaluated pain using other tools. Mean differences (MDs) were pooled using a random-effects model, and the concept of minimum clinically important difference (MCID) was considered.</p><p><strong>Results: </strong>Seventeen studies were included. All turmeric preparations significantly reduced WOMAC pain. The mean differences (MD, 95% CI) for WOMAC pain reduction were as follows: - 4.01 (-6.22, - 1.80) for conventional curcuminoid preparations (CT) plus active drug comparators (AC, defined as NSAIDs and acetaminophen), - 3.33 (-5.26, - 1.39) for AC, - 3.17 (-5.50, - 0.83) for CT, and - 2.47 (-3.27, - 1.67) for bioavailability-enhanced curcuminoid preparations (BE). The BE preparation also demonstrated a 30% reduction in WOMAC pain compared to placebo, reaching the MCID threshold. The BE + AC combination led to a 70% reduction in VAS pain compared to AC alone.</p><p><strong>Conclusions: </strong>All turmeric preparations appear to be effective in reducing knee OA pain when used as monotherapy compared to placebo. However, the certainty of evidence remains low, indicating a need for further research.</p><p><strong>Prospero registration number: </strong>CRD42023464749.</p><p><strong>Clinical trial number: </strong>not applicable.</p>\",\"PeriodicalId\":9128,\"journal\":{\"name\":\"BMC Complementary Medicine and Therapies\",\"volume\":\"25 1\",\"pages\":\"292\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309109/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Complementary Medicine and Therapies\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12906-025-05045-z\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Complementary Medicine and Therapies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12906-025-05045-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

背景:姜黄传统上被用于治疗各种炎症,包括膝骨关节炎(OA)。有多种姜黄制剂可用。然而,这些产品的相对有效性仍然未知。本研究旨在通过对随机对照试验(rct)进行系统回顾和网络荟萃分析,评估姜黄产品对膝关节OA结局的相对有效性。方法:检索截至2024年8月的PubMed、EMBASE、SCOPUS和ClinicalTrials.gov数据库,确定将姜黄制剂和/或活性比较物与安慰剂进行比较的rct。主要结果测量疼痛减轻,使用西安大略和麦克马斯特大学骨关节炎指数(WOMAC),而次要结果使用其他工具评估疼痛。使用随机效应模型汇总平均差异(MDs),并考虑最小临床重要差异(MCID)的概念。结果:纳入17项研究。所有姜黄制剂均可显著减轻WOMAC疼痛。WOMAC减轻疼痛的平均差异(MD, 95% CI)如下:常规姜黄素制剂(CT)加活性药物比较剂(AC,定义为非甾体抗炎药和对乙酰氨基酚)为- 4.01 (-6.22,- 1.80),AC为- 3.33 (-5.26,- 1.39),CT为- 3.17(-5.50,- 0.83),生物利用度增强的姜黄素制剂(BE)为- 2.47(-3.27,- 1.67)。与安慰剂相比,BE制剂还显示WOMAC疼痛减少了30%,达到了MCID阈值。与单独使用AC相比,BE + AC联合使用可使VAS疼痛减轻70%。结论:与安慰剂相比,所有姜黄制剂在单药治疗中都能有效减轻膝关节OA疼痛。然而,证据的确定性仍然很低,表明需要进一步的研究。普洛斯彼罗注册号:CRD42023464749。临床试验号:不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effect of turmeric products on knee osteoarthritis: a systematic review and network meta-analysis.

Background: Turmeric has traditionally been used to treat various inflammatory conditions, including knee osteoarthritis (OA). There are multiple turmeric preparations available. However, the comparative effectiveness of these products remains unknown. This study aimed to assess the comparative effectiveness of turmeric products for knee OA outcomes by conducting a systematic review and network meta-analysis of randomized, controlled trials (RCTs).

Methods: PubMed, EMBASE, SCOPUS, and ClinicalTrials.gov databases were searched up to August 2024, identifying RCTs that compared turmeric preparations and/or active comparators versus placebo. The primary outcome measured pain reduction, using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), while secondary outcomes evaluated pain using other tools. Mean differences (MDs) were pooled using a random-effects model, and the concept of minimum clinically important difference (MCID) was considered.

Results: Seventeen studies were included. All turmeric preparations significantly reduced WOMAC pain. The mean differences (MD, 95% CI) for WOMAC pain reduction were as follows: - 4.01 (-6.22, - 1.80) for conventional curcuminoid preparations (CT) plus active drug comparators (AC, defined as NSAIDs and acetaminophen), - 3.33 (-5.26, - 1.39) for AC, - 3.17 (-5.50, - 0.83) for CT, and - 2.47 (-3.27, - 1.67) for bioavailability-enhanced curcuminoid preparations (BE). The BE preparation also demonstrated a 30% reduction in WOMAC pain compared to placebo, reaching the MCID threshold. The BE + AC combination led to a 70% reduction in VAS pain compared to AC alone.

Conclusions: All turmeric preparations appear to be effective in reducing knee OA pain when used as monotherapy compared to placebo. However, the certainty of evidence remains low, indicating a need for further research.

Prospero registration number: CRD42023464749.

Clinical trial number: not applicable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Complementary Medicine and Therapies
BMC Complementary Medicine and Therapies INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
6.10
自引率
2.60%
发文量
300
审稿时长
19 weeks
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信